TAGAMET
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET is an injectable small-molecule drug approved by GSK in 1977 with an unknown mechanism of action and indication profile. The product is formulated for parenteral administration and represents a legacy therapeutic from the small-molecule era.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) signals declining team investment and transition-focused roles rather than growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
55 linked positions indicate active staffing on TAGAMET, predominantly in commercial and government affairs reflecting a mature asset requiring managed lifecycle and payer/regulatory engagement. Roles cluster in ViiV (GSK's specialty unit), suggesting focus on strategic positioning and stakeholder management during transition.
ViiV Healthcare Associate DirectorViiV Marketing Manager
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.